What Medi-Immune Ltd does

Medi-Immune Ltd is a United Kingdom-based micro-entity registered in Tamworth, Staffordshire, founded in 2008 and operating with approximately 6 employees. The company name suggests a healthcare or immunology orientation, though no products, services, or vertical positioning are documented in the available source material. The corporate website (https://www.medi-immune.com/) currently displays only a verification/loading screen and yields no extractable content on operations, products, customers, leadership, or financials.

No product catalog, pricing model, distribution channels, customer segments, partnerships, regulatory clearances, or strategic milestones are recorded in the input data. All enrichment fields — including headcount, technology stack, certifications, awards, funding rounds, M&A activity, and management team — are empty. The entity has no disclosed parent company, subsidiaries, investors, or public ticker, and no app or API footprint is documented.

The business model is therefore unverifiable from public sources provided. Given the 17-year operating history combined with a 6-person headcount and absence of any funding, M&A, or growth signals, the entity is most consistent with either a small inactive/dormant holding, a lifestyle consultancy, or an early-stage venture whose online presence has lapsed. No revenue, ARR, or transaction volume is disclosed. Any investment, partnership, or commercial thesis on this entity would require direct primary-source diligence (Companies House filings, direct management contact) before any characterization can be defended.

Name

Medi-Immune Ltd

Website

https://medi-immune.com

Company type

Private

Founded year

2008

Headcount range

1–10 employees

Short description

Medi-Immune Ltd is a UK-based micro-entity (6 employees, founded 2008) in Tamworth, Staffordshire. Its product, service, customer base, and business model are unverifiable from current sources, as its website returns only a verification screen with no substantive content.

Ownership category

akta.pro rank

Product category

Medical Immunology

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Immune health products
• Medical immunology
• Clinical diagnostics
• Healthcare supplies
• Therapeutic devices

Headquarters

HQ city

Tamworth, Staffordshire

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel

Core offering

Core offerings could not be determined; the company's website returned only a verification loading screen ("One moment, please...") and provided no product or service descriptions. The company name "Medi-Immune" suggests activity in medical or immunology-related fields, but no concrete offerings are evidenced.

Product overview

No product information available from the source data. The website displayed only a verification/loading page.

Differentiator

Problem solved

Functional benefit

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Expansion highlights1 record

Direct peers

• Immunovant: Clinical-stage immunology company developing anti-FcRn antibodies for autoimmune diseases; comparable specialty immunology therapeutics peer.
• Genmab: Denmark-based antibody therapeutics company with a focus on immunology and oncology; directly comparable as an immunology/biologics specialty peer.
• Novimmune: Swiss-based clinical-stage immunology company developing antibody-based therapeutics for inflammatory and immune-mediated diseases; comparable specialty immunology peer.
• Argenx: Clinical-stage immunology company developing antibody therapeutics for autoimmune diseases; comparable as a specialty immunology/antibody peer given Medi-Immune's name and likely positioning.
• Crescendo Biologics: UK-based clinical-stage biotech developing T cell engagers and immunology biologics; comparable UK-anchored, immunology-focused biotech peer.
• Immunomedics: Biopharmaceutical company developing antibody-drug conjugates for cancer and immune-mediated diseases; a relevant immunology/biologics peer.
• Biotest: Germany-based specialty biopharmaceutical company focused on immunology and hematology (plasma proteins, immunoglobulins); a relevant immunology specialty therapeutics peer.

Broad incumbents

• Ablynx (Sanofi): Nanobody-based immunology platform now part of Sanofi; comparable as an antibody/immunology specialty therapeutics peer with the broad-incumbent overlay.
• UCB: Belgian specialty biopharmaceutical company with a deep immunology portfolio (e.g., Cimzia, Evenity) plus neurology; comparable as an established immunology-focused specialty pharma peer for a UK-anchored entity named in the immunology space.
• Kymab (Sanofi): UK antibody discovery platform acquired by Sanofi; comparable as a UK-based immunology/antibody specialist peer.

Market position

Strengths1 record

Weaknesses3 records

Key risks4 records

Key highlights1 record

Customer concentration

• LinkedInlinkedin.com/company/medi-immune-ltd

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medi-Immune Ltd